Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
NASDAQ:PULM

Pulmatrix - PULM Stock Forecast, Price & News

$3.57
-0.08 (-2.19%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.53
$3.62
50-Day Range
$3.20
$4.06
52-Week Range
$3.16
$15.60
Volume
8,683 shs
Average Volume
60,336 shs
Market Capitalization
$12.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Pulmatrix MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
180.1% Upside
$10.00 Price Target
Short Interest
Healthy
1.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Pulmatrix in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($6.04) to ($6.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

396th out of 1,040 stocks

Pharmaceutical Preparations Industry

186th out of 509 stocks

PULM stock logo

About Pulmatrix (NASDAQ:PULM) Stock

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Receive PULM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter.

PULM Stock News Headlines

StockNews.com Begins Coverage on Pulmatrix (NASDAQ:PULM)
Pulmatrix Lower on Q1 Results
See More Headlines
Receive PULM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter.

PULM Company Calendar

Last Earnings
3/29/2022
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
4/04/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PULM
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+180.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-20,170,000.00
Net Margins
-387.03%
Pretax Margin
-387.03%

Debt

Sales & Book Value

Annual Sales
$5.17 million
Book Value
$16.49 per share

Miscellaneous

Free Float
3,543,000
Market Cap
$12.99 million
Optionable
Optionable
Beta
1.01

Key Executives

  • Mr. Teofilo David Raad MBA (Age 52)
    Pres, CEO & Director
    Comp: $713.51k
  • Dr. Alexander M. Klibanov Ph.D. (Age 72)
    Founder
  • Mr. Peter Ludlum CMA (Age 67)
    MBA, Interim CFO and Principal Accounting & Financial Officer
  • Dr. Aidan Curran Ph.D.
    VP of Research & Scientific Affairs
  • Dr. Margaret M. Wasilewski M.D. (Age 65)
    Chief Medical Officer
  • Mr. David J. Maki J.D. (Age 64)
    Advisor













PULM Stock - Frequently Asked Questions

Should I buy or sell Pulmatrix stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PULM shares.
View PULM analyst ratings
or view top-rated stocks.

What is Pulmatrix's stock price forecast for 2023?

1 brokerages have issued 1-year price targets for Pulmatrix's stock. Their PULM share price forecasts range from $10.00 to $10.00. On average, they anticipate the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 185.7% from the stock's current price.
View analysts price targets for PULM
or view top-rated stocks among Wall Street analysts.

How have PULM shares performed in 2022?

Pulmatrix's stock was trading at $8.76 at the beginning of the year. Since then, PULM stock has decreased by 60.0% and is now trading at $3.50.
View the best growth stocks for 2022 here
.

When is Pulmatrix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our PULM earnings forecast
.

How were Pulmatrix's earnings last quarter?

Pulmatrix, Inc. (NASDAQ:PULM) released its earnings results on Tuesday, March, 29th. The biotechnology company reported ($2.43) earnings per share for the quarter, missing analysts' consensus estimates of ($1.60) by $0.83. Pulmatrix had a negative trailing twelve-month return on equity of 46.03% and a negative net margin of 387.03%.

When did Pulmatrix's stock split?

Pulmatrix shares reverse split before market open on Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK).

What is Pulmatrix's stock symbol?

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

Who are Pulmatrix's major shareholders?

Pulmatrix's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.31%) and Vanguard Group Inc. (1.30%).
View institutional ownership trends
.

How do I buy shares of Pulmatrix?

Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pulmatrix's stock price today?

One share of PULM stock can currently be purchased for approximately $3.50.

How much money does Pulmatrix make?

Pulmatrix (NASDAQ:PULM) has a market capitalization of $12.74 million and generates $5.17 million in revenue each year.

How can I contact Pulmatrix?

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The official website for the company is www.pulmatrix.com. The biotechnology company can be reached via phone at (781) 357-2333, via email at rclarke@pulmatrix.com, or via fax at 707-525-9906.

This page (NASDAQ:PULM) was last updated on 11/28/2022 by MarketBeat.com Staff